Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Merkel Cell 21Melanoma 9Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Sezary Syndrome 1Sarcoma 1Primary Myelofibrosis 1Mycosis Fungoides 1Motor Activity 1Microsatellite Instability 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 17Tacrolimus 15Cyclophosphamide 15Antilymphocyte Serum 12Methotrexate 11Whole-Body Irradiation 10Mycophenolic Acid 10Busulfan 10Cyclosporine 9Psychiatric Rehabilitation 8Melphalan 8Methylprednisolone 7Flow Cytometry 7Radiotherapy 6Filgrastim 6Etoposide 6Therapeutics 5Sirolimus 5Polymerase Chain Reaction 5Ondansetron 4sargramostim 3Early Intervention, Educational 3Cord Blood Stem Cell Transplantation 3Aprepitant 3merphos 2liposomal amphotericin B 2fludarabine 2Prednisone 2Pentetic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × avelumab × Dermatologic × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡